150 related articles for article (PubMed ID: 36401154)
1. Refractory idiopathic multicentric Castleman disease responsive to sirolimus therapy.
Bayram E; Pehlivan UA; Fajgenbaum DC; Paydas S
Am J Hematol; 2023 Feb; 98(2):361-364. PubMed ID: 36401154
[No Abstract] [Full Text] [Related]
2. A case of tocilizumab-refractory idiopathic multicentric Castleman's disease successfully treated with sirolimus.
Sumiyoshi R; Koga T; Furukawa K; Umeda M; Yamamoto K; Mori R; Kawakami A
Clin Immunol; 2021 Dec; 233():108887. PubMed ID: 34798240
[TBL] [Abstract][Full Text] [Related]
3. An open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman disease: Study protocol for an investigator-initiated, multicenter, open-label trial (SPIRIT compliant).
Koga T; Takemori S; Hagimori N; Morimoto S; Sumiyoshi R; Shimizu T; Hosogaya N; Fukushima C; Yamamoto H; Kawakami A
Medicine (Baltimore); 2020 Dec; 99(50):e23291. PubMed ID: 33327255
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial.
Koga T; Hagimori N; Takemori S; Morimoto S; Sumiyoshi R; Shimizu T; Hosogaya N; Fukushima C; Yamamoto H; Kawakami A
Medicine (Baltimore); 2020 Jul; 99(30):e20710. PubMed ID: 32791665
[TBL] [Abstract][Full Text] [Related]
5. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.
Fajgenbaum DC; Langan RA; Japp AS; Partridge HL; Pierson SK; Singh A; Arenas DJ; Ruth JR; Nabel CS; Stone K; Okumura M; Schwarer A; Jose FF; Hamerschlak N; Wertheim GB; Jordan MB; Cohen AD; Krymskaya V; Rubenstein A; Betts MR; Kambayashi T; van Rhee F; Uldrick TS
J Clin Invest; 2019 Aug; 129(10):4451-4463. PubMed ID: 31408438
[TBL] [Abstract][Full Text] [Related]
6. Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO.
Phillips AD; Kakkis JJ; Tsao PY; Pierson SK; Fajgenbaum DC
J Cell Mol Med; 2022 Jun; 26(11):3147-3152. PubMed ID: 35488725
[TBL] [Abstract][Full Text] [Related]
7. Daratumumab for the treatment of refractory idiopathic multicentric Castleman disease: a case report.
Shi Y; Li J; Zhang L
Ann Hematol; 2022 Nov; 101(11):2529-2531. PubMed ID: 35927344
[No Abstract] [Full Text] [Related]
8. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.
Lust H; Gong S; Remiker A; Rossoff J
Pediatr Blood Cancer; 2021 Oct; 68(10):e29261. PubMed ID: 34302703
[TBL] [Abstract][Full Text] [Related]
9. Aseptic Meningitis-retention Syndrome Associated with Tocilizumab in a Patient with Idiopathic Multicentric Castleman Disease.
Arakawa A; Iizuka M; Matsuda S; Matsubara E; Yamazaki H; Yoshikawa N; Tanaka H; Yoshizawa T
Intern Med; 2021 Dec; 60(24):3995-3998. PubMed ID: 34219105
[TBL] [Abstract][Full Text] [Related]
10. Indolent T-Lymphoblastic Proliferation in Idiopathic Multicentric Castleman Disease.
Karki NR; Arfa AS; Savage N; Kutlar A
Acta Haematol; 2022; 145(2):214-220. PubMed ID: 34818661
[TBL] [Abstract][Full Text] [Related]
11. Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?
Abid MB; Peck R; Abid MA; Al-Sakkaf W; Zhang Y; Dunnill GS; Staines K; Sequeiros IM; Lowry L
Hematol Oncol; 2018 Feb; 36(1):320-323. PubMed ID: 28401573
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Idiopathic Castleman Disease.
van Rhee F; Greenway A; Stone K
Hematol Oncol Clin North Am; 2018 Feb; 32(1):89-106. PubMed ID: 29157622
[TBL] [Abstract][Full Text] [Related]
13. Cerebral thrombotic event as a rare complication in a young female patient with idiopathic multicentric castleman disease.
Yin H; Zhang L; Pan B; Zhao J; Feng J; Li J
Clin Neurol Neurosurg; 2020 Nov; 198():106246. PubMed ID: 33032104
[No Abstract] [Full Text] [Related]
14. How we manage idiopathic multicentric Castleman disease.
Brandstadter JD; Fajgenbaum DC
Clin Adv Hematol Oncol; 2022 Sep; 20(9):564-571. PubMed ID: 36125948
[No Abstract] [Full Text] [Related]
15. Targeting the mTOR pathway in idiopathic multicentric Castleman disease.
Stern RM; Berliner N
J Clin Invest; 2019 Oct; 129(10):4086-4088. PubMed ID: 31524635
[TBL] [Abstract][Full Text] [Related]
16. Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports.
Ferrero S; Ragaini S
J Med Case Rep; 2021 Mar; 15(1):105. PubMed ID: 33676575
[TBL] [Abstract][Full Text] [Related]
17. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.
Yu L; Shi M; Cai Q; Strati P; Hagemeister F; Zhai Q; Li L; Fang X; Li J; Sun R; Zhang S; Yang H; Wang Z; Qian W; Iwaki N; Sato Y; Zhang L; Li J; Oksenhendler E; Xu-Monette ZY; Young KH
Oncologist; 2020 Nov; 25(11):963-973. PubMed ID: 32852137
[TBL] [Abstract][Full Text] [Related]
18. Sustained remission of severe Multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance.
Turcotte LM; Correll CK; Reed RC; Moertel CL
Pediatr Blood Cancer; 2014 Apr; 61(4):737-9. PubMed ID: 24019247
[TBL] [Abstract][Full Text] [Related]
19. Brief communication: rituximab in HIV-associated multicentric Castleman disease.
Bower M; Powles T; Williams S; Davis TN; Atkins M; Montoto S; Orkin C; Webb A; Fisher M; Nelson M; Gazzard B; Stebbing J; Kelleher P
Ann Intern Med; 2007 Dec; 147(12):836-9. PubMed ID: 18087054
[TBL] [Abstract][Full Text] [Related]
20. Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.
van Rhee F; Rossi JF; Simpson D; Fosså A; Dispenzieri A; Kuruvilla J; Goh YT; Cho SG; Capra M; Liu T; Casper C; Cavet J; Wong RS
Br J Haematol; 2021 Jan; 192(1):e28-e31. PubMed ID: 33128769
[No Abstract] [Full Text] [Related]
[Next] [New Search]